CRISPR Therapeutics (NASDAQ:CRSP) Hits New 1-Year Low – What’s Next?

CRISPR Therapeutics AG (NASDAQ:CRSP)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $36.70 and last traded at $37.04, with a volume of 992191 shares. The stock had previously closed at $39.69.

Analyst Ratings Changes

CRSP has been the subject of a number of research reports. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Barclays dropped their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Bank of America dropped their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $78.38.

CRISPR Therapeutics Trading Down 4.1 %

The firm’s 50 day simple moving average is $46.17 and its 200-day simple moving average is $48.60. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of -13.45 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the previous year, the business earned ($1.41) earnings per share. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the transaction, the chief executive officer now directly owns 196,540 shares in the company, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.10% of the stock is currently owned by insiders.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. State Street Corp increased its position in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after acquiring an additional 599,304 shares during the period. FMR LLC increased its holdings in shares of CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after purchasing an additional 23,075 shares during the period. Geode Capital Management LLC raised its position in shares of CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after buying an additional 35,196 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of CRISPR Therapeutics by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock valued at $51,326,000 after buying an additional 19,094 shares during the period. Finally, Baker BROS. Advisors LP grew its position in CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after buying an additional 743,075 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.